A multicentre study comparing mazindol and placebo in obese patients

Area of Science:

• Pharmacology
• Obesity Research

Background:

• Mazindol's distinct chemical profile differentiates it from amphetamine anorectics, suggesting a potentially safer side-effect and abuse profile.
• The efficacy of mazindol as a weight-loss agent requires further elucidation through controlled clinical trials.

Purpose of the Study:

• To evaluate the efficacy and safety of mazindol in promoting weight loss in obese patients over a six-week period.
• To compare the effects of mazindol monotherapy, behavioral modification alone, and combination therapy on weight reduction.

Main Methods:

• A six-week, double-blind, placebo-controlled study involving 245 obese patients across four centers.
• Patients were randomized into mazindol or placebo groups, with one center incorporating behavioral modification alongside the assigned treatment.

Main Results:

• Mazindol therapy did not produce significant clinical or laboratory abnormalities.
• Patients receiving placebo without behavioral modification showed no weight loss and had a higher dropout rate.
• Both mazindol monotherapy and behavioral modification alone led to a significant mean weight loss of 1 pound/patient/week.
• Combination therapy with mazindol and behavioral modification resulted in a greater mean weight loss (1.5 pounds/patient/week) compared to behavioral modification alone.

Conclusions:

• Mazindol is a safe and effective option for the initial treatment of obesity.
• Behavioral modification is effective for weight loss, and its efficacy is enhanced when combined with mazindol.
• Mazindol therapy demonstrates value in managing obesity, particularly when integrated with lifestyle interventions.